Clinical Trial Update: Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update describes a three-drug combination (sorafenib, bevacizumab, and oxaliplatin) for metastatic malignant melanoma. The study is Phase 1/Pha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Avastin (bevacizumab)
• Eloxatin (oxaliplatin)
• Nexavar (Sorafenib)

Snippet

Sponsor: San Diego Pacific Oncology & Hematology Associates | Conditions: Melanoma (Skin) | Phase 1, Phase 2 | Status: UNKNOWN